Role of surgery in the management of Ovarian cancer. Waseem Kamran Sub-speciality Fellow Surgical Gynaecological Oncology St James Hospital

Size: px
Start display at page:

Download "Role of surgery in the management of Ovarian cancer. Waseem Kamran Sub-speciality Fellow Surgical Gynaecological Oncology St James Hospital"

Transcription

1 Role of surgery in the management of Ovarian cancer Waseem Kamran Sub-speciality Fellow Surgical Gynaecological Oncology St James Hospital

2 Role of surgery Prevention Diagnosis Staging Treatment Palliative

3 Prevention surgery-rrso Gene Mutation BRCA1 BRCA2 (Up to 60%).

4 Diagnosis Ovarian cystic mass > 5cm; no regression for 6-8 weeks Solid ovarian lesion Any ovarian lesion with papillary vegetations on cyst wall (TVUS) Any adnexal mass > 10 cm Ascites Palpable adnexal mass in prepubertal/postmen-pausal Torsion / Rupture suspected

5 Types of Surgery-1 Staging Surgery A thorough exploration to assess the extent of disease % of presumed early cancers have occult peritoneal and lymphatic metastasis Primary cytoreduction Refers to the initial surgical excision of tumour and tumour involved organs prior to chemotherapy. Optimal surgical cytoreduction is defined as residual tumour less than 1 cm.

6 Types of Surgery-2 Interval cytoreduction surgery Cytoreduction on patients who have previously received neoadjuvant chemotherapy. Second look Surgery refers to the surgical management of recurrent ovarian cancer Surgery for bowel obstruction

7 Staging Procedure-1 Vertical midline laparotomy Thorough examination of abdominal viscera Quantify the disease Peritoneal washings, biopsies Frozen sections Systemic lymph adenectomy

8 Staging Procedure-2 Early stage cancer Examination with systemic lymphadenectomy 1 in 4 early stage cancers get upstaged to IIIC (Maggioni A, 2006) Advanced stage cancer Role of systematic lymphadenectomy is unclear Not a prognostic factor No correlation between nodal status and survival (Parazzini F, 1999) increased progression-free survival compared to the no lymphadenectomy arm: 31.2% vs 21.6% (Panici PB, 2005)

9 Primary Cytoreduction-1 Cornerstone of the initial surgical management Indicated in patient deemed suitable for optimal cytoreduction (less than 1cm residual disease, GOG) Careful selection of patients Performace status Nutrition status Medical co-morbidities Impending bowel obstruction

10 Primary cytoreduction-2 Optimal cytoreduction Controversial definition: No prospective randomized control trials to define the degree of residual disease that has the best clinical outcome. GOG: <1cm Disease > 1.5 cm: poor prognostic indicator (Griffi ths CT, 1975, 1979)

11 Primary cytoreduction-3 Confined to the pelvis: TAH, BSO Appendectomy, ± bowel resection Omentectomy Pelvic and para-aortic lymph adenectomy Conservative surgery (Fertility saving) Upper abdominal disease May also include spleenectomy, nephrectomy, cholecystectomy, hepatic and diaphram resection etc

12 Primary cytoreduction-4 Volume of residual disease inversely correlates with survival (Bristow RE, Hoskins WJ, Eisenkop SM et al) No residual disease shows improved overall survival and progression-free survival. Chi et al, 2006 reported the following median overall survival rates Size NVD <5mm 0.6-1cm 1-2cm >2cm Survival (months)

13 Primary cytoreduction-5 Improves symptoms bloating, abdominal distention, or abdominal pain Often involves aggressive surgery High peri-operative morbidity May delay subsequent chemo-therapy

14 Sub-optimal debulking-1 Optimal debulking is not always feasible Limiting factors: Extensive upper abdominal Retroperitoneal disease Large tumor burden in bowel Mesentery, or porta hepatis.

15 Sub-optimal debulking-2 Selection criteria often used to determine which patients cannot be optimally cytoreduced Include presence of stage IV disease, massive ascites, bulky omental disease, splenic involvement, and suprarenal lymphadenopathy If optimal debulking not possible, then the operation is generally limited to a TAH & BSO and/or omentectomy

16 Sub-optimal debulking-3 Clinical models : Computed tomography (CT) scans have been evaluated to determine their predictivevalue in identifying unresectable disease ( Nelson et al) Not very accurate Do not consider tumour biology and surgeon s expertise Decision largely remains clinical

17 Sub-optimal debulking-4 The majority of women will receive adjuvant chemotherapy after suboptimal debulking Role of subsequent attempt of debulking surgery is unclear Survival benefit results contradictory Burg et al, 1995 (EORTC trial): improved survival ( 26 vs 20 months) Rose PG (GOG 152 trial), 2004: No difference in PFS or overall survival (32 vs 33 months)

18 Interval cytoreduction surgery-1 Patients with massive ascites, large bilateral pleural effusions, extensive upper abdomen and retroperitoneal lymphadenopathy may benefit from neoadjuvant chemotherapy Patients with favourable response to chemotherapy and improved performance and nutritional status are considered for interval debulking surgery.

19 Interval cytoreduction surgery-2 In numerous retrospective and prospective case-control studies interval debulking has shown to be associated with decreased morbidity when compared to initial cytoreductive surgery in advanced ovarian cancer Overall survival rates are similar (Primary Vs Interval cytoreduction) Results of a randomized control study, Chemotherapy or Upfront Surgery (CHORUS) awaited

20 Role of minimally invasive surgery-1 Feasible for early ovarian cancer In assessing resectability of advanced disease prior to laparotomy In second-look procedures. Decreased morbidity and shorter hospitalization Operative time of 120 to 240 minutes has been reported with laparoscopic staging of ovarian cancer

21 Role of minimally invasive surgery-2 Complications include vascular and gastrointestinal injuries. Formation of port site metastases, particularly in the setting of carcinomatosis. Rupture and dissemination of the contents (15-25%)

22 Second look surgery Either laparotomy or laparoscopy To determine the disease status in an asymptomatic patient who has no clinical evidence off disease and has completed the planned number of chemotherapy cycles To determine end point for chemotherapy The value in laparoscopy lies mostly in its positive predictive value If unresectable disease: laparotomy can be avoided If negative: Laparotomy may be undertaken

23 Secondary cytoreduction surgery-1 May be performed in some cases of disease recurrence Limited data regarding the benefits of secondary cytoreductive surgery Secondary cytoreduction may be considered in subgroup With progression-free interval of 12 to 18 months from completion of adjuvant chemotherapy Localized recurrence Amenable to complete cytoreduction in potentially chemosensitive disease Good performance status

24 Secondary cytoreduction surgery-2 Aim is complete cytoreduction Patients with optimal secondary cytoreduction (< 1 cm) survived for 16 to 60 months, compared to 8 to 27 months for those patients with residual diseases 1 cm (Tebes SJ, 2007; Santillan A, 2007; Benedetti Panici P, 2007) As with primary surgery, the biology of the cancer is an important confounding factor.

25 Surgery for bowel obstruction-1 Some patients with recurrent ovarian cancer will develop small and/or large bowel obstruction Patients are often end-stage and malnourished, with substantial chemoresistant tumour burden Palliative surgery is controversial and requires skilled patient selection Multifactorial: Mechanical blockage include Dense mesenteric infiltration, carcinomatosis, and adhesions.

26 Surgery for bowel obstruction-2 Possible palliative procedures: Bowel resection, colostomy, or intestinal bypass or gastrostomy tube Re-obstruction rate is 10-50% Factors associated with successful palliation include absence of the following (Jong et al, 1995): 3 litres of ascites, multifocal obstruction, palpable bulky tumour, and preoperative weight loss 9 kg.

27 Conclusion Despite significant progress in chemotherapy and biologic therapy, surgery remains an important modality in the treatment of ovarian cancer Despite the benefits of surgical intervention, the specific biology of a patient s disease is central to her response to chemotherapy, duration of remission, and ultimate survival.

28 Thank You

Cytoreductive surgery in Ovarian Cancer. Arjun Jeyarajah, Consultant Gynaecological Oncologist, St Bartholomew s Hospital, London.

Cytoreductive surgery in Ovarian Cancer. Arjun Jeyarajah, Consultant Gynaecological Oncologist, St Bartholomew s Hospital, London. Cytoreductive surgery in Ovarian Cancer Arjun Jeyarajah, Consultant Gynaecological Oncologist, St Bartholomew s Hospital, London. Ovarian Cancer 6,600 new cases per year 4,000 deaths 75% of cases have

More information

UNIVERSITÉ D'AUVERGNE

UNIVERSITÉ D'AUVERGNE LAPAROSCOPY and OVARIAN CANCER J. DAUPLAT Clermont-Ferrand France UNIVERSITÉ D'AUVERGNE CLERMONT 1 1 - PROPHYLACTIC OOPHORECTOMY 2 - DIAGNOSIS 3 - EARLY STAGES : STAGING 4 - ADVANCED STAGES - ASSESSMENT

More information

Ovarian cancer: Surgery, when and how preferably? P. Mathevet CHUV, UNIL

Ovarian cancer: Surgery, when and how preferably? P. Mathevet CHUV, UNIL Ovarian cancer: Surgery, when and how preferably? P. Mathevet CHUV, UNIL Ovarian tumor context More than 70% of cases are diagnosed at an advance stage (stage IIIC-IV). The extension occurs through the

More information

Robotics in the Modern Era of Ovarian Cancer Management

Robotics in the Modern Era of Ovarian Cancer Management Robotics in the Modern Era of Ovarian Cancer Management Ginger J. Gardner, MD Gynecology Service, Department of Surgery Memorial Sloan-Kettering Cancer Center Objectives Advantages of Minimally Invasive

More information

Optimizing First Line Treatment of Advanced Ovarian Cancer

Optimizing First Line Treatment of Advanced Ovarian Cancer Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology

More information

Overview of Gynaecologic Cancer

Overview of Gynaecologic Cancer Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms

More information

Ovarian Cancer. Andreas Obermair. Gynaecological Oncologist

Ovarian Cancer. Andreas Obermair. Gynaecological Oncologist Ovarian Cancer Andreas Obermair Gynaecological Oncologist www.obermair.info Ovarian cancer in QLD Five patients with ovarian cancer per week in QLD. Two patients will be diagnosed in early stage (stage

More information

Surgical Staging of Endometrial Cancer

Surgical Staging of Endometrial Cancer Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging

More information

surface malignancies. The objectives of the talk today will be to provide an introduction to

surface malignancies. The objectives of the talk today will be to provide an introduction to MOHAMMED HAROON ASIF CHOUDRY, MD 1 Good morning, my name is Haroon Choudry, I m on faculty in the Division of Surgical Oncology at the University of Pittsburgh. The focus of my talk today will be on the

More information

Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care

Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care Manitoba Outline Ovarian Cancer Types Current Standard IV

More information

Recent Advances in the Surgical Management of Ovarian Cancer

Recent Advances in the Surgical Management of Ovarian Cancer Recent Advances in the Surgical Management of Ovarian Cancer Neil S. Horowitz, M.D. Assistant Professor, Harvard Medical School Division of Gynecologic Oncology Brigham and Women s/dana Farber Ovarian

More information

Ovarian Cancer. Josie Rutovitz

Ovarian Cancer. Josie Rutovitz Ovarian Cancer Josie Rutovitz Extent of the Problem In 2006 = 9 th most common cancer in women (Aust Institute of Health and Welfare). 1226 new cases in 2006. 60% of cases are post menopausal. 47% increase

More information

Costing statement: Ovarian cancer: the recognition and initial management of ovarian cancer

Costing statement: Ovarian cancer: the recognition and initial management of ovarian cancer Costing statement: Ovarian cancer: the recognition and initial management of ovarian cancer 1 Resource impact The guideline on ovarian cancer (NICE clinical guideline 122) is unlikely to have a significant

More information

Staging and Surgical Approaches in Gastric Cancer

Staging and Surgical Approaches in Gastric Cancer Guideline 2-19 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Staging and Surgical Approaches in Gastric Cancer N. Coburn, R. Cosby, L. Klein, G. Knight, R.

More information

Luis D. Carcorze Soto, MD PGY-3

Luis D. Carcorze Soto, MD PGY-3 Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:

More information

Ultra-radical surgery in Ovarian Cancer Where s the evidence?

Ultra-radical surgery in Ovarian Cancer Where s the evidence? Ultra-radical surgery in Ovarian Cancer Where s the evidence? John Tidy Professor of Gynaecological Oncology Sheffield RCTs of surgery in Ovarian Cancer Interval debulking Neoadjuvant chemotherapy Neither

More information

Sybile Val, MD Department of Surgery. October 29, 2009

Sybile Val, MD Department of Surgery. October 29, 2009 Soft Tissue Tumors Sybile Val, MD Department of Surgery SUNY Downstate Medical Center October 29, 2009 Case Presentation 52 YOM presented to ED on 7/22 with 52 YOM presented to ED on 7/22 with abdominal

More information

Charles Zaloudek, MD Professor Department of Pathology UCSF. Ovarian Epithelial Tumors. Case 1. Case 1 Gross Pathology

Charles Zaloudek, MD Professor Department of Pathology UCSF. Ovarian Epithelial Tumors. Case 1. Case 1 Gross Pathology Charles Zaloudek, MD Professor Department of Pathology UCSF Ovarian Epithelial Tumors Case 1 68 year old woman Bilateral adnexal masses Elevated CA125 (793) Hysterectomy in 2008 Underwent BSO and tumor

More information

INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 28 No 1, 2007 1 4

INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 28 No 1, 2007 1 4 INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 28 No 1, 2007 1 4 Original Article-II Primary Versus Interval Cytoreductive Surgery in Treatment of Advanced Ovarian Cancer ABDUL RASHID LONE, MUSHTAQ

More information

SURGERY DEBATES Neoadjuvant Chemotherapy vs Primary Surgical Cytoreduction

SURGERY DEBATES Neoadjuvant Chemotherapy vs Primary Surgical Cytoreduction 9 th International Conference on Ovarian Cancer - 2011 SURGERY DEBATES Neoadjuvant Chemotherapy vs Primary Surgical Cytoreduction Dennis S. Chi, M.D. Gynecology Service, Department of Surgery Memorial

More information

Common Surgical Procedures Gyn/Oncology

Common Surgical Procedures Gyn/Oncology Malignancy Description Codes wrvu Comments Cervical Typical Open Cone biopsy 57520 4.11 Leep conization 57522 3.67 Colposcopy/Leep 57461 3.43 TAH +/- BSO 58150 17.31 Radical hysterectomy +/- BSO (Total,

More information

Keywords: advanced stage ovarian cancer, tertiary cytoreduction, debulking surgery

Keywords: advanced stage ovarian cancer, tertiary cytoreduction, debulking surgery CASE PRESENTATION ROJSP 2016, Vol. I (issue 1): E 45-53. Extended upper abdominal resections as part of debulking surgery at the time of tertiary cytoreduction for relapsed ovarian cancer a case report

More information

MANAGEMENT OF OVARIAN CYSTS

MANAGEMENT OF OVARIAN CYSTS MANAGEMENT OF OVARIAN CYSTS Management of Suspected Ovarian Masses in Premenopausal Women In premenopausal women almost all ovarian masses and cysts are benign. The overall incidence of a symptomatic ovarian

More information

Renal Cell Carcinoma Solitary Renal Mass

Renal Cell Carcinoma Solitary Renal Mass Renal Cell Carcinoma Solitary Renal Mass (Page 1 of 8) PRESEN- TATION Solitary renal mass Initial CT of abdomen and pelvis CBC, Na, K, CO BUN, creatinine, alkaline phosphatase, calcium, albumin Potential

More information

PROGNOSTIC FACTORS IN ADVANSED OVARIAN CANCER

PROGNOSTIC FACTORS IN ADVANSED OVARIAN CANCER PROGNOSTIC FACTORS IN ADVANSED OVARIAN CANCER Dr. Hisham Rahahle Gynecologist, MD, Ph.D Subspecialty in Gynecological Oncology E-mail: hisham_re@yahoo.com Abstract: This study includes (68) patient diagnosed

More information

Epithelial Ovarian Cancer

Epithelial Ovarian Cancer Epithelial Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Risk Factors Incessant ovulation Early menarche, late menopause, low parity Family history Acquired genetic mutations

More information

Ovarian Cancer. Peter Sykes 2011

Ovarian Cancer. Peter Sykes 2011 Ovarian Cancer Peter Sykes 2011 Ovarian cancer is important Site New cases Deaths uterus 314 78 ovary 312 3% 173 5% cervix 180 65 vulva 42 12 other 26 20 Total gynae 864 348 colon 1262 571 breast 2362

More information

Ovarian cancer. A guide for journalists on ovarian cancer and its treatment

Ovarian cancer. A guide for journalists on ovarian cancer and its treatment Ovarian cancer A guide for journalists on ovarian cancer and its treatment Contents Contents 2 3 Section 1: Ovarian Cancer 4 i. Types of ovarian cancer 4 ii. Causes and risk factors 5 iii. Symptoms and

More information

PERITONEAL THERAPY IN OVARIAN CANCER, ROBERT P. EDWARDS, MD 1

PERITONEAL THERAPY IN OVARIAN CANCER, ROBERT P. EDWARDS, MD 1 PERITONEAL THERAPY IN OVARIAN CANCER, ROBERT P. EDWARDS, MD 1 Good morning, my name is Dr. Robert Edwards and I m going to be discussing peritoneal therapy in the treatment of women with ovarian cancer.

More information

Progress in Pancreatic Cancer

Progress in Pancreatic Cancer Progress in Pancreatic Cancer Gina Vaccaro, MD OHSU Medical Oncology September 2014 1 Anatomy of the pancreas DePinho, Nature Reviews, 2002 Pancreatic tumor types Ductal adenocarcinoma (>85%) Acinar cell

More information

M. R. C H R I S T I A E N S M D P H D M U L T I D I S C I P L I N A I R B O R S T C E N T R U M L E U V E N

M. R. C H R I S T I A E N S M D P H D M U L T I D I S C I P L I N A I R B O R S T C E N T R U M L E U V E N Metastatic Breast Cancer: A Surgical Challenge M. R. C H R I S T I A E N S M D P H D M U L T I D I S C I P L I N A I R B O R S T C E N T R U M L E U V E N Traditional and new concepts MBC has a bad prognosis:

More information

Results of Interval Debulking Surgery Compared with Primary Debulking Surgery in Advanced Stage Ovarian Cancer

Results of Interval Debulking Surgery Compared with Primary Debulking Surgery in Advanced Stage Ovarian Cancer Results of Interval Debulking Surgery Compared with Primary Debulking Surgery in Advanced Stage Ovarian Cancer Philippe Morice, MD, Gil Dubernard, MD, Annie Rey, BS, David Atallah, MD, Patricia Pautier,

More information

Management of the primary in Stage IV colorectal cancer. Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto

Management of the primary in Stage IV colorectal cancer. Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto Stage IV Colorectal Cancer 15%-20% CRC patients present

More information

Quick Facts about Appendix Cancer

Quick Facts about Appendix Cancer Quick Facts about Appendix Cancer What is the appendix? The appendix is a pouch-like tube attached to the first part of the large intestine (cecum). The appendix is about 10 centimetres long and has no

More information

NEOADJUVANT CHEMOTHERAPY IN OVARIAN CANCER: A SYSTEMATIC REVIEW

NEOADJUVANT CHEMOTHERAPY IN OVARIAN CANCER: A SYSTEMATIC REVIEW NEOADJUVANT CHEMOTHERAPY IN OVARIAN CANCER: A SYSTEMATIC REVIEW APRIL 2008 PREPARED BY NATIONAL BREAST AND OVARIAN CANCER CENTRE FUNDED BY THE AUSTRALIAN GOVERNMENT DEPARTMENT OF HEALTH AND AGEING 1 Neoadjuvant

More information

Evidence tabel Lokaal palliatieve behandelingen

Evidence tabel Lokaal palliatieve behandelingen Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Mazin Al-kasspooles, MD Associate Professor of Surgery Division of Surgical Oncology Director, Regional Therapy

More information

Ovarian cysts Diagnosis and Management

Ovarian cysts Diagnosis and Management Ovarian cysts Diagnosis and Management Mr P K Athanasias MRCOG Consultant Gynaecologist St Anthony s Hospital pathanasias@gmail.com Introduction ovary is an ovum-producing reproductive organ located in

More information

Pancreatic Tumors. Margo Shoup, MD Associate Professor of Surgery Loyola University Medical Center

Pancreatic Tumors. Margo Shoup, MD Associate Professor of Surgery Loyola University Medical Center Margo Shoup, MD Associate Professor of Surgery Loyola University Medical Center Introduction 38,000 cases a year Risk factors Smoking Pancreatitis Real risk, but only 5% of pancreatic cancer patients Genetics

More information

Peritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA

Peritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Peritoneal Surface Malignancies Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Cancer dissemination routes Hematogenous metastases Lymphatic metastases Implants on peritoneal surfaces Surgically

More information

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011 Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

More information

The Role of Laparoscopy in Endometrial Cancer

The Role of Laparoscopy in Endometrial Cancer The Role of Laparoscopy in Endometrial Cancer Prof. Dr. Tugan BEŞE İstanbul University, Cerrahpaşa Medical Faculty Gynecologic Oncology Department Surgical staging in Endometrial Cancer Laparoscopic surgery

More information

MEDICAL PROTOCOL ONCOLOGICAL MANAGEMENT OF OVARIAN CANCER

MEDICAL PROTOCOL ONCOLOGICAL MANAGEMENT OF OVARIAN CANCER MEDICAL PROTOCOL ONCOLOGICAL MANAGEMENT OF OVARIAN CANCER These guidelines have been developed by members of the Gynaecological Oncology Guidelines Group, for approval by the Merseyside and Cheshire Gynaecological

More information

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards

More information

Medical Policy Number: R-9 Issue Date: September 2015 Responsible Department: Implementation Date: October 2015 Clinical Operations

Medical Policy Number: R-9 Issue Date: September 2015 Responsible Department: Implementation Date: October 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PET SCAN CPT Code: 78811 - Limited area e.g. Chest, head/neck 78812 - Skull base to mid thigh 78813 - Whole Body 78814 With CT attenuation (Limited

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063 PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi

More information

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:

More information

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis T. Christopher Windham, M.D., F.A.C.S. Medical Director, Florida Hospital

More information

Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer

Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer DOI:http://dx.doi.org/10.7314/APJCP.2015.16.6.2369 RESEARCH ARTICLE Role of Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer Dan Zhao 1, Ling-Ying Wu 1 *, Xiao-Bing Wang 2, Xiao-Guang

More information

Staging of Colorectal Cancer Pareen Mehta, MD and Patrick M Colletti, MD

Staging of Colorectal Cancer Pareen Mehta, MD and Patrick M Colletti, MD Staging of Colorectal Cancer Pareen Mehta, MD and Patrick M Colletti, MD Colorectal carcinoma remains one of the leading causes of cancer death in the United States and worldwide. In fact, the approximate

More information

Does laparoscopy improve diagnosis and treatment decision-making in suspected ovarian cancer?

Does laparoscopy improve diagnosis and treatment decision-making in suspected ovarian cancer? PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation research project.

More information

Recommendations for cross-sectional imaging in cancer management, Second edition

Recommendations for cross-sectional imaging in cancer management, Second edition www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Ovarian cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Ovarian cancer 3 Clinical background 3

More information

Adenocarcinoma of the Colon and Rectum

Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Colon and Rectum Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee Colorectal CA 3 rd most commonly diagnosed CA

More information

Management of Bile Duct Problems Treatment Overview

Management of Bile Duct Problems Treatment Overview Management of Bile Duct Problems Treatment Overview Bile Duct Obstruction Bile duct (or biliary) obstruction occurs for numerous reasons. Causes can include cancerous and non-cancerous processes as well

More information

Laparoscopic Management of Early Stage Endometrial Cancer

Laparoscopic Management of Early Stage Endometrial Cancer Laparoscopic Management of Early Stage Endometrial Cancer B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G. Mage Early Stage of Endometrial Cancer most of cases diagnosed (clinical

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer

Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer Original Article Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer Hong Zheng, Yu-Nong Gao Key Laboratory of Carcinogenesis

More information

Peter Reichardt. Berlin, Germany

Peter Reichardt. Berlin, Germany Peter Reichardt Berlin, Germany Background Workshop 3/04 in Lugano, Switzerland under the auspices of ESMO Panel experts Pathology Molecular biology Imaging Surgery Medical oncology Methodology for clinical

More information

Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages

Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages Med. J. Cairo Univ., Vol. 83, No. 2, March: 63-68, 2015 www.medicaljournalofcairouniversity.net Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages

More information

Management of Suspicious Adnexal Masses

Management of Suspicious Adnexal Masses Management of Suspicious Adnexal Masses Operative Techniques and Results Polyclinique Clermont-Ferrand France Surgical Management of Suspicious Adnexal Masses 2 Steps Diagnosis Treatment Surgical Management

More information

Mucinous Cystadenoma of the Ovary

Mucinous Cystadenoma of the Ovary Case Studies [1] September 24, 2012 By Harpreet Singh, MD [2] A 50-year-old female with a history of progressive abdominal distention and discomfort for six months. A 50-year-old female with a history

More information

Optimum Surgery in Advanced-stage Ovarian Cancer

Optimum Surgery in Advanced-stage Ovarian Cancer Optimum Surgery in Advanced-stage Ovarian Cancer June 2011 Optimum Surgery in Advanced-stage Ovarian Cancer 1. Introduction In advanced-stage ovarian cancer, the evidence base from randomised controlled

More information

How to treat early gastric cancer. Surgery

How to treat early gastric cancer. Surgery How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies

More information

Revised RECIST guidelines (v 1.1)

Revised RECIST guidelines (v 1.1) Revised RECIST guidelines (v 1.1) Response evaluation criteria in solid tumors was first published in 2000 Since its publication, the validity of unidimensional measurement has been confirmed in multiple

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Chemotherapy for Advanced Ovarian Cancer. Jennifer E. Vaughn, MD MSPH Blue Ridge Cancer Care Department of Medicine, VTC School of Medicine

Chemotherapy for Advanced Ovarian Cancer. Jennifer E. Vaughn, MD MSPH Blue Ridge Cancer Care Department of Medicine, VTC School of Medicine Chemotherapy for Advanced Ovarian Cancer Jennifer E. Vaughn, MD MSPH Blue Ridge Cancer Care Department of Medicine, VTC School of Medicine Learning Objectives Understand the principles of first-line therapy

More information

Colon, Rectum and Anus

Colon, Rectum and Anus Colon, Rectum and Anus Medical Student Lecture Mazin Al-kasspooles Department of Surgery University of Kansas Medical Center 34 y.o. female Several year h/o constipation, on chronic laxatives. Getting

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma. Cytoreductive Surgery

The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma. Cytoreductive Surgery The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma Robert A. Figlin MD., FACP Acting Director City of Hope Comprehensive Cancer Center Cytoreductive Surgery

More information

Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer

Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer PREAMBLE The following recommendations regarding the safe performance of laparoscopic resection for curable colon and rectal cancer

More information

Landmark Trials in Ovarian Cancer

Landmark Trials in Ovarian Cancer Landmark Trials in Ovarian Cancer Where we ve been and where we re headed Erin E. Stevens, MD Gynecologic Oncology Billings Clinic Cancer Center February 28, 2015 Health Care, Education and Research www.billingsclinic.com

More information

Gastric Cancer in a Young Postpartum Female. Kings County Hospital Center SUNY Downstate Case Conference March 22, 2012

Gastric Cancer in a Young Postpartum Female. Kings County Hospital Center SUNY Downstate Case Conference March 22, 2012 Gastric Cancer in a Young Postpartum Female Kings County Hospital Center SUNY Downstate Case Conference March 22, 2012 Case HPI: xx yo F, G5P3, xx weeks s/p C-section, with gastric outlet obstruction.

More information

PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS. A08/S/f Colorectal: Cytoreductive surgery (Adult)

PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS. A08/S/f Colorectal: Cytoreductive surgery (Adult) A08/S/f 2013/14 NHS STANDARD CONTRACT FOR COLORECTAL: CYTOREDUCTIVE SURGERY (ADULT) PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS Service Specification No. Service Commissioner Lead

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

BORDERLINE RESECTABLE PANCREATIC CANCER

BORDERLINE RESECTABLE PANCREATIC CANCER BORDERLINE RESECTABLE PANCREATIC CANCER Douglas B. Evans For the Multidisciplinary Pancreatic Tumor Study Group Departments of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston,

More information

Frequently Asked Questions About Ovarian Cancer

Frequently Asked Questions About Ovarian Cancer Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues

More information

ENDOMETRIAL CANCER THE IMPORTANCE OF PELVIC & PARA-AORTIC AORTIC NODES

ENDOMETRIAL CANCER THE IMPORTANCE OF PELVIC & PARA-AORTIC AORTIC NODES ENDOMETRIAL CANCER THE IMPORTANCE OF PELVIC & PARA-AORTIC AORTIC NODES International Federation of Gynecologic and Obstetrics (FIGO) inaccurate 1978 1988 Clinical Staging System a paradigm shift Operative

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Epithelial Ovarian Cancer

Epithelial Ovarian Cancer Page 1 of 7 CLINICAL PRESENTATION INITIAL EVALUATION PRIMARY TREATMENT Pelvic Mass Diagnosis by previous surgery Pelvic ultrasound CA 125 CXR CT scan if concern for malignancy Other tumor markers if indicated

More information

GYNAECOLOGY DEPARTMENT

GYNAECOLOGY DEPARTMENT GYNAECOLOGY DEPARTMENT Should you require copies of the correspondence between the hospitals? And your family GP, Please do not hesitate to ask for this during your consultation. CANCER OF THE OVARY Patient

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Review Article When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?

Review Article When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place? Oncology Volume 2010, Article ID 852028, 6 pages doi:10.1155/2010/852028 Review Article When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place? Igor E. Martinek and Sean Kehoe Oxford

More information

Gastric MALT Lymphoma

Gastric MALT Lymphoma Gastric MALT Lymphoma Gastric MALT lymphomas develop in the stomach. Helicobacter pylori ( H. pylori) infection has a critical role in the pathogenesis of this disease and its eradication can lead to tumor

More information

PANCREATIC CANCER. Two different categories of cancer can affect the pancreas: Exocine and Endocrine cancers

PANCREATIC CANCER. Two different categories of cancer can affect the pancreas: Exocine and Endocrine cancers PANCREATIC CANCER INTRODUCTION More than 42,000 Americans develop cancer of the pancreas each year; it is the fourth leading cause of cancer-related death in the United States. Two different categories

More information

The Adnexal Mass and Early Ovarian Cancer

The Adnexal Mass and Early Ovarian Cancer The Adnexal Mass and Early Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Never give in. Never give in. Never, never, never, never- in nothing great or small, large or petty-

More information

Ovarian cancer A guide for journalists on ovarian cancer and its treatment

Ovarian cancer A guide for journalists on ovarian cancer and its treatment Ovarian cancer A guide for journalists on ovarian cancer and its treatment Contents Contents 2 3 Section 1: Ovarian Cancer 4 i. Types of ovarian cancer 4 ii. Causes and risk factors 5 iii. Symptoms and

More information

Kaplan Medical Center

Kaplan Medical Center Local lth Therapy Following Primary Systemic Therapy (PST) In LABC Noa Ben Baruch, MD Kaplan Medical Center Which LABC Are We Talking About Advanced primary tumors o T3 Advanced regional lymph nodes o

More information

Radiofrequency ablation of a liver metastasis from mucinous adenocarcinoma of the ovary

Radiofrequency ablation of a liver metastasis from mucinous adenocarcinoma of the ovary Biological and Biomedical Reports, 2013, 3(1), 1-6 Case Report Radiofrequency ablation of a liver metastasis from mucinous adenocarcinoma of the ovary Naoya Harada *, Ichiro Nobuhara, Noriko Haruta, and

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

Guideline for the Management of Endometrial Cancer Formerly the Guideline for Post Menopausal Bleeding and Endometrial Cancer

Guideline for the Management of Endometrial Cancer Formerly the Guideline for Post Menopausal Bleeding and Endometrial Cancer Guideline for the Management of Endometrial Cancer Formerly the Guideline for Post Menopausal Bleeding and Endometrial Cancer Date Approved by Network Governance May 2012 Date for Review May 2015 Changes

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

WHAT S NEW IN BREAST IMAGING

WHAT S NEW IN BREAST IMAGING WHAT S NEW IN BREAST IMAGING Patricia Hassell BCCA Magnetic Resonance Imaging Positron Emission Tomography/PET Ultrasound Digital Mammography 1 BREAST MRI Improved spatial resolution of surface coils Use

More information

Navigating the Nomenclature of Appendiceal Mucinous Neoplasms. Overview. Clinical History. Pseudomyxoma peritonei. Mucinous tumors of the appendix

Navigating the Nomenclature of Appendiceal Mucinous Neoplasms. Overview. Clinical History. Pseudomyxoma peritonei. Mucinous tumors of the appendix Navigating the Nomenclature of Appendiceal Mucinous Neoplasms Rhonda K. Yantiss, M.D. Professor of Pathology and Laboratory Medicine Weill Cornell Medical College, New York, NY Overview Pseudomyxoma peritonei

More information

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors. Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)

More information

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE STUDY COORDINATOR: Jimmy Chung, MD 234 Surgical breast cancer patients admitted 2004-2008 Updated: 10/7/10 INTRODUCTION Breast cancer is

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017

More information